OmniAb Investor Presentation Deck

Intellectual Property Advantage PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES CAN CREATE DIVERSE AND DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL Over 300 patents issued worldwide ● • We maintain a broad intellectual property estate with multiple long duration patent families covering each major element of our technology platform • Licenses are structured so that royalties are linked to the patents for the antibodies discovered with OmniAb, thereby creating a lengthy coverage tail ~80 patent filings by our partners claiming an OmniAb-derived antibody as primary invention, with expiries up to 2042 Antibody Patent Applications Filed by Partners 80 60 40 20 O 2014 2015 2016 2017 2018 2019 2020 2021 2022 25 OmniAb

View entire presentation